The wide range of contributions to this volume, from a detailed paper on the use of gene therapy in combination with hypothermia for the treatment of cerebral ischemia to a comprehensive poster describing the role of anesthetic agents in neurotoxicity during development and senescence, illustrate the scientific scope presented.

Contributions from clinical and basic science researchers from many disciplines address various approaches to providing neuroprotection. The clinical focus is on the complexity of neuroprotection, the need for understanding the time-course effects of hypoxia/ischemia, and the need for combinational and time-course applications of multiple therapies. New technologies are introduced for describing both the insult and the treatment necessary for neuroprotection, including gene expression assays (genomics) and gene therapy.

Several chapters are devoted to the examination of the predictive value of models for outcome measures in clinical ischemic stroke neuroprotective trials. The need to move from in vitro models to more predictive in vivo approaches with the use of pharmacokinetics is addressed. Other chapters emphasize the role of endogenous agents such as nitric oxide, melatonin, L-carnitine, and estrogens in acute and chronic neural injury and therapy.

NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.

ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit www.nyas.org/membership/main.asp for more information about becoming a member.